Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 2/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29672053 | 1.00 | NFE2L2 (0.37) | NFE2L2BTKMEN1KMT2AALDH1A1 | |
| SCHEMBL4917719 | 0.78 | ALDH1A1 (0.40) | KMT2AALDH1A1KDM4ETSHR | |
| SCHEMBL28279220 | 0.77 | NFE2L2 (0.34) | NFE2L2MEN1KMT2AAPLNRAURKA | |
| SCHEMBL896225 | 0.77 | NFE2L2 (0.34) | NFE2L2MEN1KMT2AAPLNRAURKA | |
| SCHEMBL1475054 | 0.77 | GAA (0.34) | — | |
| SCHEMBL607884 | 0.74 | APLNR (0.40) | BTKMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6852244 | 0.74 | CCR1 (0.35) | ALDH1A1KDM4E | |
| SCHEMBL29060479 | 0.74 | NFE2L2 (0.33) | NFE2L2APLNR | |
| SCHEMBL6938627 | 0.74 | CYP1A2 (0.42) | ALDH1A1CYP2A6MAPTKDM4E | |
| SCHEMBL1474575 | 0.72 | KCNJ1 (0.38) | ALDH1A1CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113348170-B | Biphenyl derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-3541792-B1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3541792-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | Amgen Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2018097944-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| EP-2868660-B1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING AN IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-12-27 | — | — | EP | disclosed |
| EP-2868660-B1 | ANTITUMOR EFFECT POTENTIATOR COMPRISING AN IMIDAZOOXAZINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2017-12-27 | — | — | EP | disclosed |
| US-9375434-B2 | Antitumor effect potentiator composed of imidazooxazine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9375434-B2 | Antitumor effect potentiator composed of imidazooxazine compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-28 | — | — | US | disclosed |
| CN-1630650-A | Nitrogen-containing heterocyclic compound and drug containing same | EISAI CO LTD (JP) | 2005-06-22 | — | — | CN | disclosed |
| WO-2005040159-A1 | 4-(PYRAZOL-3-YLAMINO) PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2005-05-06 | — | — | WO | disclosed |
| US-6864265-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2005-03-08 | — | — | US | disclosed |
| EP-1484327-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND MEDICINE THEREOF | Eisai Co., Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-08-26 | — | — | US | disclosed |
| CN-1457339-A | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2003-11-19 | — | — | CN | disclosed |
| EP-1317445-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-01-23 | — | — | US | disclosed |
| WO-2002022600-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220207-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | NFE2L2 2933/4885BTK 2049/4885MEN1 4289/4885 |
| US-20190275008-A1 | TRIAZOLE FURAN COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, APLNR | NFE2L2 3130/4885BTK 3645/4885MEN1 4005/4885 |
| US-20030018046-A1 | Chemokine receptor binding heterocyclic compounds | CXCR3, ACKR3, CCR2 | NFE2L2 2933/4885BTK 2049/4885MEN1 4289/4885 |
| US-10736883-B2 | Triazole furan compounds as agonists of the APJ receptor | TBXA2R, AGTR1, APLNR | NFE2L2 3130/4885BTK 3645/4885MEN1 4005/4885 |
| US-20040167224-A1 | Nitrogen containing heterocyclic compounds and medicines containing the same | NQO1, CBR1, NOX1 | NFE2L2 78/4885BTK 3040/4885MEN1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.